Skip to content
  • YouTube
  • Facebook
  • LinkedIn
Pharm'Up

Pharm'Up

An E-platform for Learners

https://www.youtube.com/watch?v=xuTKPPZrxy4
Primary Menu
  • Home
  • News
  • Industries
  • Disease
  • Drugs
  • Events
  • Jobs
  • Trainings
  • Conferences
  • Syllabus
  • Previous Papers
  • Notes
  • Colleges
Live
  • Home
  • 2025
  • November
  • 5
  • FDA Confirms Contaminated Syrups Not Exported to U.S.; India Recalls Products
  • Pharma Jobs

FDA Confirms Contaminated Syrups Not Exported to U.S.; India Recalls Products

Pharm'Up 2 min read

The U.S. Food and Drug Administration (FDA) confirmed it is aware of ongoing and severe contamination involving diethylene glycol (DEG) and ethylene glycol (EG) in certain children’s cough and cold medicines in India.1 The agency stated that these contaminated products have not been shipped to the United States.2

India’s Central Drugs Standard Control Organisation (CDSCO) also informed the FDA that the affected medicines were not exported from India to any other country.3


Contaminated Products and Recalls in India

The CDSCO has identified and recalled several cough syrups contaminated with DEG and EG, which are industrial solvents toxic to humans.4

Recalled ProductManufacturerContamination Status
ColdrifSresan PharmaceuticalsConfirmed DEG/EG contamination
Re-Life SyrupShape Pharma Pvt. Ltd.Confirmed DEG/EG contamination
Respifresh-TRRednex Pharmaceuticals Pvt. Ltd.Confirmed DEG/EG contamination
Dextromethorphan Hydrobromide SyrupKaysons Pharma Ltd.Recalled as a precaution; India’s testing did not detect DEG/EG.

FDA and CDSCO Safety Measures

Both the FDA and CDSCO have taken steps to address the contamination issue and prevent future occurrences:

  • FDA Actions:
    • Maintains strict safeguards to prevent unsafe drugs from being imported into the U.S.5
    • Contacted drug manufacturers to reinforce the need to comply with Current Good Manufacturing Practices (cGMP) and meet proper quality specifications.6
    • Issued 2023 guidance, Testing of Glycerin for Diethylene Glycol, to alert the industry to the need for rigorous raw material and finished drug testing.7
    • Coordinating with the World Health Organization (WHO) and communicating with the CDSCO.8
  • CDSCO Actions (Post-Incident): Following the contamination cases, the CDSCO and various state authorities have significantly tightened domestic regulations, including:
    • Ordering an immediate halt to production at the implicated manufacturing sites and suspending product authorizations.9
    • Mandating that manufacturers test all raw materials (like glycerin, propylene glycol, and sorbitol) for DEG and EG prior to use, with a permissible limit not exceeding 0.10%.10
    • Issuing directives for rigorous batch testing of finished oral liquid products for DEG/EG.11

Risk of DEG/EG Poisoning

Diethylene glycol and ethylene glycol poisoning can be severe and life-threatening, especially in children.12

  • Early Symptoms: Low energy, abdominal pain, vomiting, and diarrhea.13
  • Progressed Symptoms: Shortness of breath, rapid breathing, and coma.14
  • Severe Complications: Within days, poisoning can cause kidney failure, liver damage, brain or nervous system injury, and death.15

The FDA advises against giving over-the-counter medications for cough and cold symptoms to children under 2 years of age due to the potential for serious side effects, and encourages reporting of adverse events through its MedWatch Safety Information and Adverse Event Reporting Program.

About the Author

Pharm'Up

Author

An E-platform for Pharma Learners

View All Posts

Post navigation

Previous: AstraZeneca Strikes Landmark Deal with Trump Administration Cuts U.S. Drug Prices, Commits $50 Billion to Domestic Manufacturing
Next: WHO Initiates Development of First Global Guidelines on HTLV-1 Testing and Prevention

Related Stories

Pharmup 19
1 min read
  • Pharma Jobs

Pharmacovigilance Specialist Opportunity at Bausch + Lomb

Pharm'Up
Pharmup 18
1 min read
  • Pharma Jobs

Career Opportunity: Formulation & Development (Injectable) at Derren Healthcare

Pharm'Up
Pharmup 17
2 min read
  • Pharma Jobs

Sun Pharma Recruitment: Manager – EU Compliance (Tandalja R&D)

Pharm'Up

Recent Posts

  • Navigating Balance Disorders: Causes, Symptoms, and Management
  • Understanding Seasonal Allergic Rhinitis: Causes, Symptoms, and Relief
  • Pharmacovigilance Specialist Opportunity at Bausch + Lomb
  • Career Opportunity: Formulation & Development (Injectable) at Derren Healthcare
  • Sun Pharma Recruitment: Manager – EU Compliance (Tandalja R&D)

Recent Comments

No comments to show.

Archives

  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025

Categories

  • Colleges
  • Conferences/ Workshops
  • Disease
  • Drugs
  • Events
  • Industries
  • Notes
  • Pharma Jobs
  • Pharma News
  • Previous Papers
  • Syllabus
  • Trainings/ Courses
  • Uncategorized

Read These Too

Pharmup 21
2 min read
  • Disease

Navigating Balance Disorders: Causes, Symptoms, and Management

Pharm'Up
Pharmup 20
1 min read
  • Disease

Understanding Seasonal Allergic Rhinitis: Causes, Symptoms, and Relief

Pharm'Up
Pharmup 19
1 min read
  • Pharma Jobs

Pharmacovigilance Specialist Opportunity at Bausch + Lomb

Pharm'Up
Pharmup 18
1 min read
  • Pharma Jobs

Career Opportunity: Formulation & Development (Injectable) at Derren Healthcare

Pharm'Up
  • YouTube
  • Facebook
  • LinkedIn
Copyright ©Pharm'UP All rights reserved by Eduversity India | MoreNews by AF themes.